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Abstract
Background: Despite the substantial improvement that antimigraine
drugs brought to migraineurs, there is the need for a long-acting and better
tolerated migraine treatment than actual pharmacotherapy. St. John’s
wort (SJW), a medicinal plant endowed with a favourable tolerability
profile, showed numerous bioactivities. We here investigated the
pain-relieving property of SJW and its main components, hypericin and
flavonoids, in a mouse model induced by nitric oxide (NO) donors
administration.
Methods: The NO donors nitroglycerin and sodium nitroprusside (SNP)
induced allodynia (cold plate test) and hyperalgesia (hot plate test).
Western blotting experiments were performed to detect c-Fos and protein
kinase C (PKC) expression within periaqueductal grey matter (PAG).
Results: A single oral administration of an SJW dried extract (5 mg/kg
p.o.) produced a prolonged relief from pain hypersensitivity. Similarly,
preventive SJW administration increased the latency to the induction of
hyperalgesia and reduced the duration of the painful symptomatology.
Among SJW main components, hypericin showed a similar profile of
activity, whereas flavonoids were devoid of any antihyperalgesic effect. To
clarify the cellular pathways involved in the SJW mechanism of action, we
examined the effects induced by the herbal drug on PKC. NO donors’
administration upregulated and increased phosphorylation of PKCg and
PKCe isoforms within PAG that was prevented by SJW treatment. The
absence of behavioural side effects or altered animals’ locomotor activity
by SJW was demonstrated.
Conclusions: These results suggest SJW as a safe therapeutic perspective
for migraine pain, and indicate PKC as an innovative target for
antimigraine therapy.
1. Introduction
In the past two decades, experimental and clinical
research has led to considerable advances in under-
standing the pathophysiological mechanisms of
migraine, and new options for acute and prophylactic
treatment have emerged. The discovery of triptans
was the most significant step forward in the treatment
of acute migraine, but not all migraineurs respond to
triptans, and many who do benefit from them have
troublesome adverse effects or do not experience sus-
tained pain relief (Ferrari et al., 2001). For this reason,
there is still a significant need for well-tolerated new
drugs that provide effective, quick and sustained relief
from migraine pain (Ferrari et al., 2010; Weatherall
et al., 2010; Diener et al., 2011). A number of drugs
belonging to various pharmacological classes and
deliverable by several routes are now available both
for the acute and the preventive treatments of
migraine (Magis and Schoenen, 2011; Olesen and
Ashina, 2011). Nevertheless, disability and satisfaction
remain low in many subjects because treatments are
not accessible, not optimized, not effective or simply
not tolerated.
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Hypericum perforatum L., commonly called St. John’s
wort (SJW), has been used for centuries as medicinal
plant. More recently, it has received attention for its
efficacy against mild to moderate depression, compa-
rable to that of standard antidepressants, with a
favourable incidence of side effects (Kasper et al.,
2010). Despite pharmacological studies on SJW that
have focused on its antidepressant activity, some
studies have documented other bioactivities produced
by this herbal plant, such as antibacterial (Saddiqe
et al., 2010) and antiviral (Birt et al., 2009) activities.
SJW is also endowed with anti-inflammatory activity
following not only topic (Sosa et al., 2007), but also
systemic administration (Mattace Raso et al., 2002).
Recently, the analgesic activity against acute pain
(Galeotti et al., 2010a) and the capability to relieve
neuropathic pain in different animal models (Galeotti
et al., 2010b) were observed after oral administration
of SJW.
Based on the data implicating the anti-
inflammatory, analgesic and antineuropathic bioac-
tivities of SJW, we investigated the efficacy of a SJW
dried extract in an animal model of meningeal noci-
ception induced by administration of nitric oxide (NO)
donors to evaluate its potential antimigraine activity.
Hypericum extract contains at least 10 active constitu-
ents that may contribute to its pharmacological effects
(Greeson et al., 2001). Among them, phloroglucinols
(e.g. hyperforin), naphthodianthrones (e.g. hypericin)
and the flavonoids (e.g. hyperoside, quercetin) are the
most abundant ones and the main responsible agents
for the traditional use of this herbaceous plant. The
role of the SJW main components was also investi-
gated in order to elucidate their involvement in the
modulation of pain perception. Furthermore, elucidat-
ing the cellular mechanism of action of SJW might
help clarify the pathophysiology of migraine. We,
then, investigated the influence on key molecules
involved in pain sensation by SJW and components.
In particular, we focused our attention on the modu-
lation of the activity of protein kinase C (PKC), a
family of enzymes highly involved in pain perception
(Velazquez et al., 2007).
2. Materials and methods
2.1 Animals
Male Swiss albino mice (20–22 g) from the Morini
(San Polo d’Enza, Italy) breeding farm were used. Ten
mice were housed per cage (26 ¥ 41 cm). The cages
were placed in the experimental room 24 h before the
test for acclimatization. The animals were fed a stan-
dard laboratory diet and tap water ad libitum, and kept
at 23  1 °C with a 12-h light/dark cycle, light on at 7
a.m. All experiments were carried out in accordance
with the European Communities Council Directive of
24 November 1986 (86/609/EEC). All efforts were
made to minimize animal suffering and to reduce the
number of animals used.
2.2 Drug administration
2.2.1 Behavioural studies
The NO donors nitroglycerin (GNT) (10 mg/kg, Bioin-
dustria L.I.M., Italy), dissolved in 10% ethylene glycol
in saline (0.9% NaCl), and sodium nitroprusside (SNP)
(1 mg/kg, Sigma, Italy), dissolved in saline, were
administered intraperitoneally (i.p.) as previously
reported (Tassorelli et al., 2003), and the behavioural
tests were performed 1–6 h after intraperitoneal
administration.
Hypericum perforatum (SJW) dried extract containing
0.32% of total hypericins (Indena Research Laborato-
ries, Settala, Milan, Italy), hypericin, hyperoside,
quercetin and amentoflavone (Sigma, Milan, Italy)
were dissolved in 1% carboxymethylcellulose solution
immediately before use and administered by oral
gavage. The doses of hypericin (0.01 mg/kg), querce-
tin (0.0415 mg/kg), amentoflavone (0.0029 mg/kg)
and hyperoside (0.3175 mg/kg) correspond to the
amount of each component present in a 5-mg/kg
preparation of SJW dried.
To evaluate the capability of SJW to counteract the
pain hypersensitivity produced by NO donors, the
herbal drug and its main components were adminis-
tered 150 min after GTN or SNP. Ergotamine tartrate
(0.1 mg/kg i.p.) and indomethacin (1 mg/kg i.p.) (Cal-
biochem, Milan, Italy), used as antimigraine reference
drugs, and the PKC blocker calphostin C [0.05–0.2 mg
What’s already known about this topic?
• A number of antimigraine drugs belonging to
different pharmacological classes are available,
which brought a substantial improvement
in the migraineurs’ quality of life. However,
there is the need for a long-acting and better
tolerated migraine treatment than current
pharmacotherapy.
What does this study add?
• SJW might represent a long-acting, safe and tol-
erable perspective for antimigraine therapy.
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per mouse intracerebroventricularly (i.c.v.)] (Calbio-
chem, Milan, Italy) were administered 150 min after
NO donors.
To investigate the activity of SJW to prevent NO
donor-induced hypersensitivity to pain, SJW, hyperi-
cin, ergotamine and indomethacin were administered
30 min before GNT or SNP treatment, whereas
calphostin C was administered 5 min before NO
donors.
Vehicles used to dissolve drugs were tested for the
absence of any effect on pain threshold in comparison
with saline-treated and naïve mice.
2.2.2 Western blotting experiments
Experiments were conducted on periaqueductal grey
matter (PAG) of naïve and GTN- and SNP-treated
mice. Brain areas were removed 1 or 4 h after NO
donors’ administration. For time course experiments,
PAG was removed 1, 2, 4 and 6 h after NO donors’
administration.
Doses and administration schedules of compounds
used were chosen on the basis of time course and
dose-response curves performed in our laboratory.
Intracerebroventricular (i.c.v.) administration was
performed under ether anaesthesia, as previously
described (Galeotti et al., 2003). Briefly, during anaes-
thesia, mice were grasped firmly by the loose skin
behind the head. A 0.4-mm external diameter, hypo-
dermic needle attached to a 10-ml syringe was inserted
perpendicularly through the skull and no more than
2 mm into the brain of the mouse, where 5 ml were
then administered. The injection site was 1 mm to the
right or left from the midpoint on a line drawn
through to the anterior base of the ears. Injections
were performed into the right or left ventricle ran-
domly. To ascertain that the drugs were administered
exactly into the cerebral ventricle, some mice (20%)
were injected with 5 ml of diluted 1:10 India ink and
their brains examined macroscopically after section-
ing. The accuracy of the injection technique was
evaluated, and the percentage of correct injections was
determined to be 95%. Drug concentrations were pre-
pared so that the necessary dose could be administered
in a volume of 5 ml per mouse.
2.3 Cold plate
For assessment of cold allodynia, mice were placed on
a cold plate that is maintained at a temperature of
4  0.1 °C. Reaction times (s) were measured with a
stopwatch before and 1, 2, 4 and 6 h after administra-
tion of the NO donors. The time between placements
of a mouse on the plate and licking or lifting of a hind
paw was measured with a digital timer. An arbitrary
cut-off time of 60 s was adopted. Ten to fifteen mice
per group were tested.
2.4 Hot plate
Mice were placed inside a stainless steel container,
which was set thermostatically at 50.0  0.1 °C in a
precision water bath from KW Mechanical Workshop,
Siena, Italy. Reaction times (s) were measured with a
stopwatch before and 1, 2, 4 and 6 h after administra-
tion of the NO donors. The endpoint used was the
licking of the fore or hind paws. An arbitrary cut-off
time of 60 s was adopted. Ten to fifteen mice per group
were tested.
2.5 Motor coordination
The motor coordination was assessed by using the
rotarod test. The apparatus consisted of a base plat-
form and a rotating rod with a diameter of 3 cm and a
non-slippery surface. The rod was placed at a height of
15 cm from the base. The rod, 30 cm in length, was
divided into five equal sections by six disks. Thus, up
to five mice were tested simultaneously on the appa-
ratus, with a rod-rotating speed of 16 r.p.m. The integ-
rity of motor coordination was assessed on the basis of
the number of falls from the rod in 30 s. Those mice
scoring less than three and more than six falls in the
pretest were rejected (20%). The number of falls was
measured before (pretest) and 1, 2, 4 and 6 h after the
administration of the NO donors. Ten mice per group
were used.
2.6 Locomotor activity
The locomotor activity was evaluated by using the
hole-board test. The apparatus consisted of a 40-cm
square plane with 16 flush mounted cylindrical holes
(3 cm diameter) distributed 4 by 4 in an equidistant,
grid-like manner. Mice were placed at the centre of
the board one by one and allowed to move about
freely for a period of 5 min each. Two photobeams,
crossing the plane from midpoint to midpoint of oppo-
site sides, thus dividing the plane into four equal
quadrants, automatically signalled the movement of
the animal (counts in 5 min) on the surface of the
plane (locomotor activity). Miniature photoelectric
cells, in each of the 16 holes, recorded (counts in
5 min) the exploration of the holes (exploratory activ-
ity) by the mice. Experiments were performed 4 h
after administration of the NO donors. Ten mice per
group were tested.
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2.7 Western blot analysis
Samples to conduct Western blotting experiments were
collected 1 or 4 h after the GTN (10 mg/kg i.p.) or SNP
(1 mg/kg i.p.) treatment. PAG was homogenized in an
homogenization buffer containing 25 mM Tris-HCl
pH = 7.5, 25 mM NaCl, 5 mM EGTA, 2.5 mM EDTA,
2 mM NaPP, 4 mM PNFF, 1 mM Na3VO4, 1 mM PMSF,
20 mg/ml leupeptin, 50 mg/ml aprotinin, 0.1% SDS.
The homogenate was centrifuged at 9000 xg for 15 min
at 4 °C, the low speed pellet was discarded. Protein
concentration was quantified using Bradford’s method
(protein assay kit, Bio-Rad Laboratories, Milan, Italy).
Membrane homogenates (10 mg) made from PAG of
GTN-, SNP-treated and naïve mice were separated on
10% SDS-PAGE, and transferred onto nitrocellulose
membranes (90 min at 120 V) using standard proce-
dures. Membrane were blocked in PBST (PBS contain-
ing 0.1% Tween) containing 5% nonfat dry milk for
120 min. Following washings, blots were incubated
overnight at 4 °C with specific antibodies against PKCg
phosphorylated on Thr514 (pPKCg, 1:1000 dilution);
c-Fos (1:1000) (Biosource, Camarillo, CA, USA); PKCe
phosphorylated on Ser729 (pPKCe, 1:750); PKCg
(1:1000); and PKCe (1:800) (Santa Cruz Biotechnology
Inc, CA, USA). After being washed with PBS containing
0.1% Tween, the nitrocellulose membrane was incu-
bated with goat anti-rabbit horseradish peroxidase-
conjugated secondary antisera (1:10,000) and left for
1 h at room temperature. Blots were then extensively
washed according to the manufacturer’s instruction
and developed using enhanced chemiluminescence
detection system (Pierce, Milan, Italy). Exposition and
developing time used was standardized for all the blots.
Optical density measurements were performed by
dividing the intensity of the bands by the intensity of
the housekeeping protein b-actin, used as loading
control, at each time point. Measurements in control
samples were assigned a relative value of 100%.
2.8 Statistical analysis
All experimental results were given as the mean 
standard deviation. Analysis of variance followed by
Tukey post hoc test was used for statistical analysis.
3. Results
3.1 Thermal pain hypersensitivity induced by
NO donors’ administration
To investigate the property of SJW that relieves
migraine pain, we used an animal model obtained by
administration of the NO donors SNP and nitroglyc-
erin (GTN) in mice. Administration of SNP produced
allodynia as revealed by the cold plate test (Fig. 1A).
The reaction times to the cold stimulus remained
unmodified following SNP 0.5 mg/kg i.p. Animals
treated with SNP 1 and 2 mg/kg i.p. showed reduced
reaction times between 1 and 4 h after NO donor
administration, and returned to control values 6 h
after SNP injection. Similarly, the administration
of GTN (10 mg/kg i.p.) produced cold allodynia with
a profile similar to that produced by SNP (Fig. 1B).
Following NO donors’ treatment, a thermal hy-
peralgesia was observed in the hot plate test with
a similar time course to the cold allodynia. Mice
showed reduced licking latency values 2 and
4 h after SNP (1 mg/kg; Fig. 1C) and GTN adminis-
tration (10 mg/kg; Fig 1D). GTN and SNP cold allo-
dynia and heat hyperalgesia peaked after 4 h,
consistent with a typical migraine attack in
migraineurs that develops 4–6 h after GTN infusion
(Olesen et al., 1993).
c-Fos, the protein product of the immediate early
gene c-fos, has been widely used as a marker of neu-
ronal activation, and particularly, as a marker of pain
(Harris, 1998). We, therefore, detected the c-Fos
protein content in a brain area highly related to pain
perception. A rapid and progressive increase of c-Fos
expression within the PAG was observed after SNP
(1 mg/kg; Fig. 1E) and GTN administration (10 mg/kg;
Fig. 1F). The c-Fos upregulation followed the same
time course of the pain hypersensitivity observed in
cold and hot plate tests (Fig. 1A–D), showing a time
course consistent with migraine attacks in susceptible
individuals.
3.2 Effect of NO donors and SJW on mouse
locomotor activity
The NO donor-induced hypersensitivity to pain was
not accompanied by the induction of side effects. The
spontaneous mobility and exploratory activity of mice
treated with SNP (Fig. 1G) or GTN (data not shown)
were unmodified in comparison with the control
group. In the same experimental conditions,
co-administration with SJW as pretreatment (30 min
before) or treatment 150 min after NO donors did not
modify both parameters evaluated (Fig. 1G). NO
donors did not alter locomotor activity of treated
animals at any time point, as indicated by the rotarod
test results. Co-administration with SJW never modi-
fied the number of falls from the rotating rod
(Fig. 1H).
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Figure 1 NO donors decrease the pain threshold. Administration of sodium nitroprusside (SNP) at the doses of 0.5, 1, 2 mg/kg i.p. (A), or nitroglycerin
(GTN) at the dose of 10 mg/kg i.p., induces cold allodynia, evaluated in the cold plate test (B). A thermal hyperalgesia, evaluated in the hot plate test, was
also detected 2 and 4 h after SNP (1 mg/kg) (C) or GTN (10 mg/kg) injection in comparison with the corresponding vehicle-treated group, used as control
(D). NO donors modulate c-Fos expression in the PAG following SNP (E) or GTN (F) administration with a similar time course. The columns represent the
densitometric quantitation of immunoreactive protein expressed relative to control. Representative immunoblots are reported at the top of each panel.
SNP did not alter spontaneous mobility, inspection activity (hole-board test) (G) or motor coordination (rotarod test) (H) at any time point.
Co-administration with SJW did not induce any alteration of the parameters evaluated. *p < 0.05, *p < 0.01, ***p < 0.001 compared with control group.
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3.3 SJW reversed pain hypersensitivity induced
by NO donors’ administration
Oral administration of a SJW dried extract 1 mg/kg
p.o. was unable to modify pain hypersensitivity
observed in the cold plate test following SNP admin-
istration (Fig. 2A). At 5 mg/kg p.o., SJW completely
reversed the cold allodynia as shown by the reaction
times similar to control values (Fig. 2A). To elucidate
the mechanism of the antimigraine activity of SJW, we
investigated the effects produced by some of the main
components of this herbal drug administered in a con-
centration corresponding to the content present in a
5 mg/kg preparation of SJW. The administration of
hypericin (hyp; 0.01 mg/kg p.o.) reversed the cold
allodynia with a similar profile to SJW (Fig. 2B). Con-
versely, oral administration of the flavonoids querce-
tin (0.0415 mg/kg), amentoflavone (0.0029 mg/kg) or
hyperoside (0.3175) was devoid of any effect (Fig. 2C).
SJW (5 mg/kg p.o.) was able to reverse pain hyper-
sensitivity induced by GNT as well (Fig. 2D). Similar
results were obtained after oral administration of
hypericin (Fig. 2E), whereas quercetin (Fig. 2F),
amentoflavone and hyperoside (data not shown) were
unable to relieve from cold allodynia.
The administration of SWJ reversed the thermal
hyperalgesia produced by NO donors in the hot plate
test. The administration of GTN reduced the pain
threshold 2 and 4 h after administration. Oral admin-
istration of SJW counteracted this effect, showing
licking latencies values comparable to control group
(Fig. 2G). Similar results were obtained with hypericin
(Fig. 2G) and quercetin (Fig. 2H), whereas amentofla-
vone and hyperoside were devoid of any effect
(Fig. 2H). The same results were obtained against the
hyperalgesia induced by SNP (Fig. 2I).
3.4 SJW antimigraine activity requires a
PKC blockade
To confirm that the antimigraine effect of SJW was
related to the PKC-blocking properties of hypericin,
we detected the effect produced by the PKC blocker
calphostin C on cold allodynia. The administration of
calphostin C reversed the pain hypersensitivity
induced by SNP with a dose-dependent duration of
effect. At 3 h, the dose of 0.05 mg slightly increased
pain threshold without reaching the statistical signifi-
cance, at 0.1 mg counteracted the NO donors’ pain
hypersensitivity and at 0.2 mg the effect was more
prolonged being significant up to 4 h (Fig. 3A).
Calphostin C reversed the cold allodynia induced by
GTN as well (Fig. 3B). We also conduced Western blot-
ting experiments in the PAG area to detect the expres-
sion of the PKC isoforms mainly involved in pain
modulation. Time course experiments showed that
the expression of the PKCg and PKCe isoforms was
increased following NO donors’ administration, with a
peak at 2–4 h after treatment. A robust increase of the
phosphorylation of both PKC isoforms was also
detected between 1 and 4 h after GTN or SNP admin-
istration (see Fig. S1). Oral administration of SJW or
hypericin completely reversed the pPKCg (Fig. 3C)
and pPKCe upregulation (Fig. 3D) detected 4 h after
the administration of SNP or GTN in coincidence with
their counteracting effect on pain hypersensitivity
evaluated in the cold plate test. Since calphostin C is a
PKC inhibitor not-isoform specific, to validate our
results we detected the effect produced by calphostin C
on PKCg and PKCe phosphorylation. We observed a
complete prevention of pPKCg and pPKCe upregula-
tion by i.c.v. administration of the effective dose of
calphostin C 4 h after NO donors’ treatment (see
Fig. S1).
3.5 Prevention of painful symptomatology
by SJW
SJW was investigated as preventive pharmacological
treatment for painful symptomatology. Animals
received an oral administration of SJW 30 min before
injection of NO donors. Treatment was unable to com-
pletely prevent pain hypersensitivity, but the latency
to the induction of pain was increased and the dura-
tion of the painful period was shortened. The absence
of any hypersensitivity to pain was observed up to 2 h
after SNP (Fig. 4A) or GTN (data not shown) treat-
ment. Starting from 3 h after administration, NO
donor-induced allodynia was detectable also in the
SJW-treated group. Oral administration of purified
hypericin prevented cold allodynia, but starting from
2 h after NO donor treatment, the antiallodynic effect
disappeared (Fig. 4B). The administration of calphos-
tin C 5 min before NO donors prevented cold
allodynia up to 1 h towards SNP- (Fig. 4C) or GTN-
induced (Fig. 4D) hypersensitivity to pain, showing a
time course similar to hypericin.
Western blotting experiments showed that the SJW
and hypericin preventive effect was related to the
capability to prevent PKC hyperphosphorylation in
the PAG. This activity as detected 1 h after SNP or GNT
administration, in coincidence with the SJW peak of
preventive activity. Following NO donors’ treatment,
an increase of pPKCg levels was observed. A pretreat-
ment with SJW or hypericin completely prevented
PKCg hyperphosphorylation (Fig. 4E). SNP and GTN
SJW and migraine N. Galeotti, C. Ghelardini
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also increased pPKCe levels 1 h after administration,
effect completely prevented by pretreatment with SJW
or hypericin (Fig. 4F).
3.6 Effect of ergotamine and indomethacin on
NO donor-induced pain hypersensitivity
The antiallodynic effect produced by SJW and hyperi-
cin was comparable to that exerted by ergotamine
(0.1 mg/kg i.p.) and indomethacin (1 mg/kg i.p.), used
as antimigraine reference drugs, towards GTN-
(Fig. 5A) and SNP-induced (Fig. 5B) cold allodynia.
The antihyperalgesic effect produced by ergotamine
and indomethacin was of the same intensity to that
exerted by SJW.
Similarly, both reference drugs counteracted heat
hyperalgesia 3 and 4 h after GTN (Fig. 5C) or SNP
(Fig. 5D) administration, showing the same activity
profile observed with SJW.
Also, the preventive activity of SJW was similar to
that produced by ergotamine and indomethacin
towards GTN- (Fig. 5E) and SNP-induced (Fig. 5F)
cold allodynia. Both reference drugs prevented the
hypersensitivity to pain at 1 h after NO donors’
administration, whereas starting from 2 h, the NO
donor-induced allodynia was again detectable
(Fig. 5E,F).
4. Discussion
Our study showed that a single oral administration of
a SJW dried extract prevented pain hypersensitivity
and neuronal activation in a mouse model of
meningeal nociception obtained by the systemic
administration of the GTN and SNP.
A common clinical feature of an untreated migraine
attack is hyperalgesia, and allodynia affecting the
scalp, face, and contiguous regions of the neck and
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torso (Burstein et al., 2000). A single oral administra-
tion of a 5-mg/kg SJW dried extract reversed the allo-
dynia and hyperalgesia induced by NO donors,
producing a prolonged increase of pain threshold.
Allodynia has been recognized in migraine since the
19th century, with clinic- (Selby and Lance, 1960) and
population- (Bigal et al., 2008) based studies showing
that it is seen in about 75% of migraine attacks (Burst-
ein et al., 2000). Allodynia is a clinical reflection of
sensitization, and both central and peripheral sensiti-
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zations are important insofar as they both influence
attacks and perhaps disease progression (Burstein,
2001; Cooke et al., 2007). Allodynia is not only a
clinical marker for sensitization of central pain path-
ways since differences in treatment efficacy during
migraine attacks have been demonstrated based on
the presence or absence of allodynia (Burstein et al.,
2004), showing allodynia as an important marker for
treatment efficacy. The antiallodynic activity, showed
simultaneously to the antihyperalgesic activity, by
SJW appears to be of particular relevance for the treat-
ment of migraine pain.
SJW dried extract contains numerous active com-
ponents (Greeson et al., 2001). The effects produced
by the main constituents were investigated in order to
identify the component responsible for the relief from
pain and allodynia, and then to better elucidate its
mechanism of action. The naphtodiantrone hypericin
reversed pain hypersensitivity with a similar efficacy
and time course of SJW. Hypericin has long been
known to be related to pharmacological actions of
SJW. The antidepressive, antineoplastic, antitumor
and antiviral activities of hypericin have been reported
(Kubin et al., 2005), and recently its analgesic and
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antineuropathic properties have been demonstrated
(Galeotti et al., 2010a,b). We here report the antiallo-
dynic and antihyperalgesic activity of this SJW com-
ponent, suggesting it as a main constituent of the
herbal drug in the control of migraine pain.
To clarify the cellular mechanism of the antimi-
graine activity of SJW, we focused our attention on
the molecular pathways modulated by hypericin.
Enzyme assays performed on rat brain demonstrated
that hypericin is a potent and selective inhibitor of
the PKC (Takahashi et al., 1989), an enzyme highly
involved in pain modulation (Velazquez et al., 2007).
PKC is a family of serine/threonine kinases that are
divided into three groups based on calcium and dia-
cylglycerol dependence: conventional (a, bI, bII, g),
novel (d, e, h, q) and atypical (z, l/i) (Way et al.,
2000). We examined the involvement of PKCe and
PKCg since they appear to be the isoforms with a
prominent role in the modulation of pain perception
(Velazquez et al., 2007). We detected a specific
upregulation and increased phosphorylation of PKCe
and PKCg isoforms within PAG of GTN- and SNP
treated mice, and their modulation temporally
coincided with the presence of allodynia and hyper-
algesia. Oral administration of SJW and hypericin
prevented the NO donor-induced hyperphosphoryla-
tion of both PKC isoforms. The blockade of PKC
activity appears a fundamental step in the mecha-
nism of action of SJW since also its analgesic and
antineuropathic activity is related to the prevention
of cerebral PKC phosphorylation (Galeotti et al.,
2010a,b).
A role of flavonoids in the SJW-induced modulation
of pain sensation cannot be excluded since it has been
reported that flavonoids contribute to the anti-
inflammatory properties of the plant (Tedeschi et al.,
2003), and an antinociceptive activity has been dem-
onstrated for the flavonoid myricitrin (Meotti et al.,
2006). Hyperoside, the most abundant flavonoid
present in the SJW dried extract, showed neither
antiallodynic nor antihyperalgesic activity. Anti-
inflammatory and analgesic properties were reported
for the flavonoid amentoflavone (Kim et al., 2008), but
when administered in mice at a concentration corre-
sponding to the amount present in a 5-mg/kg prepara-
tion of SJW, it was devoid of any effect. Quercetin was
unable to reverse allodynia even if it resulted to be able
to relieve from heat hyperalgesia. This is not surprising
since quercetin, similarly to hypericin, is endowed with
PKC-blocking properties. A quercetin potency about 30
times lower (Ferriola et al., 1989) than hypericin
(Takahashi et al., 1989) might explain the lower effi-
cacy observed.
These results have highlighted the involvement of a
PKC-mediated pathway in the mechanism of antimi-
graine action of SJW that might reflect the presence of
a PKC hyperphosphorylation during a migraine attack
related to the induction of both allodynia and hyper-
algesia. This hypothesis is supported by clinical evi-
dence illustrating that tamoxifen, the only agent with
documented and appreciable central PKC-inhibitory
activity approved for human use (Baltuch et al.,
1993), has shown promise in treating migraine as
attested by case reports (Powles, 1986; Smitherman
and Kolivas, 2009) and clinical studies (O’Dea and
Davis, 1990; Cuzick et al., 2007). On the light of these
promising results, we can suggest PKC as an innova-
tive target for migraine pain.
SJW and hypericin, when administered before NO
donors injection, prolonged the latency to the induc-
tion of pain hypersensitivity and reduced the duration
of the painful symptomatology. These results appear of
particular relevance, suggesting SJW as a compound
that is able not only to abort a painful condition, but
also to partially prevent it. All migraine patients need
acute treatment for each attack, but those with fre-
quent attacks need also a prophylactic pharmaco-
therapy. Given that almost all current models of
migraine are acute, the number of emerging treat-
ments for acute attacks is by far much higher than the
number for prophylaxis.
The antiallodynic and antihyperalgesic effect pro-
duced by SJW is comparable to that produced by
ergotamine and indomethacin, used as reference anti-
migraine drugs. Furthermore, the dose of SJW used
(0.016 mg of total hypericins) was largely lower than
those required to induce antidepressant (1.8–2.7 mg/
die of total hypericins) (Kasper et al., 2010), analgesic
and antineuropathic activities (0.96 mg of total hyper-
icins) (Galeotti et al., 2010a,b). We can suppose that
SJW induced a selective antimigraine effect in this
animal model that is not secondary to its antidepres-
sant or analgesic property. It has been demonstrated
that the SJW bioactivities are endowed with a bell-
shaped trend (Galeotti et al., 2010a,b). This implies
that the dose of SJW to be administered should be
carefully chosen on the basis of the pharmacological
effect to be obtained.
An important drawback of the drugs used as anti-
migraine treatment is the high occurrence of side
effects. Conversely, SJW is endowed with a favourable
tolerability and safety profile (Rahimi et al., 2009). We
further demonstrated the tolerability of SJW at doses
that are able to prevent pain hypersensitivity in the
migraine model. This herbal drug neither produced
detectable modification of animals’ gross behaviour,
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nor altered locomotor activity. Recently, interactions
of SJW with prescription drugs have been reported.
SJW, at the dose recommended for the treatment of
mild to moderate depression, is a potent inducer of
cytochrome P450 enzymes, resulting in decrease
plasma concentration of a number of drugs used in
co-medication (i.e. digoxin, warfarin, oral contracep-
tives, etc.) (Whitten et al., 2006). Recent studies could
show that the degree of enzyme induction by SJW
correlates strongly with the amount of hyperforin
found in the product (Madabushi et al., 2006). We
observed that SJW counteracts pain hypersensitivity
at very low doses containing an amount of hyperforin
unable to produce clinical significant interactions
(Madabushi et al., 2006; Whitten et al., 2006).
Taken together, these data support the conclusion
that SJW prevent allodynia and hyperalgesia produced
by NO donors’ administration. These effects are sec-
ondary to the presence of hypericin that acts through
a specific inhibition of PKC activation. We can suppose
that SJW represents an important and safe therapeutic
perspective for the treatment of migraine attacks.
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Figure S1. Time course of the expression and phosphoryla-
tion of PKCg and PKCe by NO donors administration. GTN
(A) and SNP (B) increased pPKCg and pPKCe 1, 2 and 4 h
after administration, whereas at 6 h the protein levels
returned comparable to control values. Administration of
calphostin C (C; 0.2 mg per mouse i.c.v.) counteracted the
upregulation of pPKCg and pPKCe. Increased levels of total
PKCg (C) and PKCe (D) was also detected 2 and 4 h after NO
donors’ administration.
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